Shares of Athenex (ATNX) have risen by 26% since my October 5th article suggested that the stock was a Buy ahead of a key data presentation at SABCS (San Antonio Breast Cancer Symposium). It's no secret that I am a fan of platform technology stories, and here the company's promising phase 3 results for Oraxol (oral paclitaxel plus P-gp inhibitor encequidar) appeared to significantly derisk their pipeline consisting of oral versions of other commonly used chemotherapies (irinotecan, docetaxel, topotecan, eribulin, etc).
The big news at SABCS was that Oraxol provided a huge benefit